Ozmosi | Caspofungin Drug Profile

Product Description

Caspofungin injection is used in adults and children 3 months of age and older to treat yeast infections in the blood, stomach, lungs, and esophagus (tube that connects the throat to the stomach.) and certain fungal infections that could not be treated successfully with other medications. (Sourced from: https://medlineplus.gov/druginfo/meds/a615001.html)

Mechanisms of Action: Glucan Synthase Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Caspofungin

Countries in Clinic: France

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Communicable Diseases|Pneumocystis Infections|Pneumonia, Pneumocystis

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT06892951	CaspoNEB	P2	Not yet recruiting	Pneumonia, Pneumocystis\|Communicable Diseases\|Pneumocystis Infections	2026-06-01	50%	2025-03-27

Recent News Events

Date	Type	Title
10/16/2024	News Article	Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta's Portfolio of Commercial and Investigational Stage Products
09/24/2024	News Article	Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
05/23/2024	News Article	Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
04/30/2024	News Article	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Caspofungin

Alternative Names: caspofungin, CASPOFUNGINA, cancidas Clinical Status: Inactive Latest Update: 2026-02-17 Latest Update Note: Clinical Trial Update